A study of CER-1236 for certain blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an experimental cell therapy called CER-1236 for people with acute myeloid leukemia, myelodysplastic syndrome, or myelofibrosis. It aims to see if it can help treat these cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of acute myeloid leukemia or a related blood disorder.
- Your lymphocyte count must be above a certain level before the cell collection procedure.
- You should be able to perform most daily activities with little or no help.
- You cannot have had prior treatment with a permanently genetically modified cell product.
- You cannot have active autoimmune disease or a history of it needing treatment in the last 2 years, except for certain well-controlled conditions.
- You must not have a severe allergy to the drugs used in the trial or their components.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This trial tests a combination of two drugs, tagraxofusp and azacitidine, given as maintenance therapy after a stem cell transplant. The goal is to prevent the leukemia or MDS from coming back in patients whose cancer cells carry a specific marker called CD123.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
This early-phase study tests a customized immune-cell therapy (CAR-T) made from your own T cells to treat acute myeloid leukemia (AML) that has the marker CD123. It may help shrink the leukemia and improve long-term control, but the treatment is still being tested for safety and early effectiveness.
This Phase 1 trial tests a specific chemotherapy plan followed by a reduced-intensity donor stem cell transplant for people with relapsed or treatment-resistant acute myeloid leukemia (AML), certain myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It may help by using donor stem cells to rebuild the bone marrow after intensive cancer treatment, in people who are not responding well to standard therapies.
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.